Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | CCR3 | P51677 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22498129 | 0.89 | ACHE (0.62) | ACHESIGMAR1CCR3DRD4DRD2 | |
| Hydrochloric Acid SCHEMBL22498123 | 0.87 | ACHE (0.61) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL8315434 | 0.83 | ACHE (0.71) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL7363662 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL4257757 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL2010139 | 0.82 | ACHE (0.69) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL16361181 | 0.81 | CCR3 (0.71) | ACHESIGMAR1CCR3DRD4DRD2 | |
| SCHEMBL576868 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4MC4R | |
| SCHEMBL1041303 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4MC4R | |
| SCHEMBL242970 | 0.80 | SIGMAR1 (1.00) | ACHESIGMAR1CCR3DRD4MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
| EP-3458450-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-03-27 | — | — | EP | disclosed |
| CN-109153671-A | There is the active oxinane of multi-mode and thiapyran derivative for pain | 埃斯蒂文制药股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017198339-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-23 | — | — | WO | disclosed |
| WO-2013116491-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS AND METHODS FOR USING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-2569302-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen, Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2275107-A2 | Combinations for the treatment of diseases involving cell proliferation | Boehringer Ingelheim International GmbH (DE) | 2011-01-19 | — | — | EP | disclosed |
| CN-1960977-B | Quinazoline derivative | BANYU PHARMA CO LTD | 2010-07-21 | — | — | CN | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-1960977-A | Quinazoline derivative | BANYU PHARMA CO LTD (JP) | 2007-05-09 | — | — | CN | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | ACHE 81/4885SIGMAR1 2/4885CCR3 1569/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | ACHE 657/4885SIGMAR1 500/4885CCR3 1088/4885 |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | ACHE 81/4885SIGMAR1 2/4885CCR3 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.